Asset Details
Do you wish to reserve the book?
Thermophilic filamentous fungus C1-cell-cloned SARS-CoV-2-spike-RBD-subunit-vaccine adjuvanted with aldydrogel(®)85 protects K18-hACE2 mice against lethal virus challenge
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Thermophilic filamentous fungus C1-cell-cloned SARS-CoV-2-spike-RBD-subunit-vaccine adjuvanted with aldydrogel(®)85 protects K18-hACE2 mice against lethal virus challenge
Do you wish to request the book?
Thermophilic filamentous fungus C1-cell-cloned SARS-CoV-2-spike-RBD-subunit-vaccine adjuvanted with aldydrogel(®)85 protects K18-hACE2 mice against lethal virus challenge
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Thermophilic filamentous fungus C1-cell-cloned SARS-CoV-2-spike-RBD-subunit-vaccine adjuvanted with aldydrogel(®)85 protects K18-hACE2 mice against lethal virus challenge
2022
Overview
SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield, commercial-scale manufacturing to produce inexpensive vaccines/boosters for global/equitable distribution. We developed DYAI-100A85, a SARS-CoV-2 spike receptor binding domain (RBD) subunit antigen vaccine expressed in genetically modified thermophilic filamentous fungus, Thermothelomyces heterothallica C1, and secreted at high levels into fermentation medium. The RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Alhydrogel®‘85’-adjuvanted RDB-C-tag-based vaccine candidate (DYAI-100A85) demonstrates strong immunogenicity, and antiviral efficacy, including in vivo protection against lethal intranasal SARS-CoV-2 (D614G) challenge in human ACE2-transgenic mice. No loss of body weight or adverse events occurred. DYAI-100A85 also demonstrates excellent safety profile in repeat-dose GLP toxicity study. In summary, subcutaneous prime/boost DYAI-100A85 inoculation induces high titers of RBD-specific neutralizing antibodies and protection of hACE2-transgenic mice against lethal challenge with SARS-CoV-2. Given its demonstrated safety, efficacy, and low production cost, vaccine candidate DYAI-100 received regulatory approval to initiate a Phase 1 clinical trial to demonstrate its safety and efficacy in humans.
